Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (11 quarters reported)
$696M in Q4 2023 → $935M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 8.3% | Trimmed 11% | 415,307 | $77.8M |
| Abivax Sa | 7.0% | Added 5.2% | 489,889 | $65.3M |
| Axsome Therapeutics Inc. | 5.7% | Added 16% | 218,415 | $53.5M |
| Enliven Therapeutics Inc | 5.2% | Added 53% | 954,360 | $48.4M |
| Bridgebio Pharma Inc | 5.0% | Trimmed 9.0% | 633,364 | $47.2M |
| Roivant Sciences Ltd | 5.0% | Added 12% | 1,331,066 | $47.1M |
| UT United Therapeutics Corp Del | 4.9% | Trimmed 19% | 84,932 | $46M |
| Cytokinetics Inc | 4.8% | Added 86% | 527,412 | $44.9M |
| Xenon Pharmaceuticals Inc | 3.9% | Trimmed 24% | 600,200 | $36.2M |
| Celcuity Inc | 3.7% | Added 56% | 329,101 | $34.4M |
| Viridian Therapeutics Inc | 3.3% | Added 83% | 1,670,000 | $30.7M |
| Insmed Inc | 3.0% | Added 6.2% | 263,851 | $28.1M |
| UN Uniqure Nv | 3.0% | Trimmed 1.1% | 608,925 | $28M |
| Ascendis Pharma A/s | 3.0% | New | 104,877 | $28M |
| PP Praxis Precision Medicines I | 3.0% | Added 97% | 83,528 | $28M |
| Dianthus Therapeutics Inc | 3.0% | Added 29% | 285,771 | $27.9M |
| Vaxcyte Inc | 2.8% | New | 443,836 | $25.8M |
| Mirum Pharmaceuticals Inc | 2.7% | Trimmed 46% | 218,051 | $25.5M |
| PT Palvella Therapeutics Inc Ne | 2.6% | Added 5.6% | 156,450 | $23.9M |
| Cogent Biosciences Inc | 2.5% | Trimmed 36% | 602,281 | $23.3M |
| Erasca Inc | 2.4% | Added 41% | 1,221,721 | $22.4M |
| Oric Pharmaceuticals Inc | 2.3% | Unchanged | 2,017,284 | $21.8M |
| NP Newamsterdam Pharma Company | 2.1% | Added 4.3% | 582,497 | $19.7M |
| Apogee Therapeutics Inc | 2.0% | Trimmed 73% | 138,822 | $18.4M |
| Rhythm Pharmaceuticals Inc | 1.8% | New | 154,018 | $17.1M |
| Inhibrx Biosciences Inc | 1.7% | New | 164,783 | $15.6M |
| SR Scholar Rock Hldg Corp | 1.6% | Trimmed 39% | 271,227 | $14.9M |
| Oruka Therapeutics Inc | 1.6% | New | 155,343 | $14.8M |
| Kymera Therapeutics Inc | 1.3% | Trimmed 60% | 102,533 | $11.8M |
| Sionna Therapeutics Inc | 0.5% | New | 110,493 | $4.86M |
| Nuvalent Inc | 0.3% | Trimmed 93% | 26,298 | $3.25M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Apogee Therapeutics Inc | Trimmed | −374,948 | −$49.8M | 2.0% |
| Nuvalent Inc | Trimmed | −344,046 | −$42.5M | 0.3% |
| Ideaya Biosciences Inc | Exited | −873,838 | −$29.1M | — |
| Ascendis Pharma A/s | New | +104,877 | +$28M | 3.0% |
| Vaxcyte Inc | New | +443,836 | +$25.8M | 2.8% |
| Mirum Pharmaceuticals Inc | Trimmed | −182,413 | −$21.4M | 2.7% |
| Cytokinetics Inc | Added | +243,712 | +$20.8M | 4.8% |
| Ascendis Pharma A/s | Exited | −76,300 | −$17.5M | — |
| Kymera Therapeutics Inc | Trimmed | −152,139 | −$17.4M | 1.3% |
| Fulcrum Therapeutics Inc | Exited | −2,256,109 | −$17.3M | — |
Showing the 10 largest of 38 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | Trimmed | −545,355 | −$28.8M | 1.9% |
| Guardant Health Inc | Exited | −271,685 | −$27.7M | — |
| Enliven Therapeutics Inc | New | +623,839 | +$24.5M | 2.7% |
| UT United Therapeutics Corp Del | Added | +41,146 | +$24.4M | 6.9% |
| Celcuity Inc | New | +210,578 | +$24M | 2.7% |
| Argenx Se | Exited | −23,256 | −$19.6M | — |
| Dianthus Therapeutics Inc | New | +220,921 | +$18.5M | 2.1% |
| PT Palvella Therapeutics Inc Ne | New | +148,093 | +$18.5M | 2.1% |
| Revolution Medicines Inc | Trimmed | −170,009 | −$16.5M | 5.1% |
| Rhythm Pharmaceuticals Inc | Exited | −146,303 | −$15.7M | — |
Showing the 10 largest of 38 changes.
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Terns Pharmaceuticals Inc | New | +872,049 | +$35.2M | 4.0% |
| Merus N V | Exited | −372,022 | −$35M | — |
| Cogent Biosciences Inc | New | +824,283 | +$29.3M | 3.3% |
| Guardant Health Inc | New | +271,685 | +$27.7M | 3.2% |
| Arcellx Inc | Exited | −313,733 | −$25.8M | — |
| Neurocrine Biosciences Inc | Exited | −181,897 | −$25.5M | — |
| Ideaya Biosciences Inc | New | +723,653 | +$25M | 2.9% |
| Viridian Therapeutics Inc | New | +690,528 | +$21.5M | 2.5% |
| Fulcrum Therapeutics Inc | New | +1,892,683 | +$21.4M | 2.4% |
| SR Scholar Rock Hldg Corp | New | +459,727 | +$20.3M | 2.3% |
Showing the 10 largest of 38 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| UT United Therapeutics Corp Del | New | +85,318 | +$35.8M | 5.4% |
| Verona Pharma PLC | Exited | −309,988 | −$29.3M | — |
| Neurocrine Biosciences Inc | New | +181,897 | +$25.5M | 3.8% |
| Abivax Sa | New | +291,820 | +$24.8M | 3.7% |
| Intuitive Surgical Inc | Exited | −32,305 | −$17.6M | — |
| Insulet Corp | Exited | −51,408 | −$16.2M | — |
| Tg Therapeutics Inc | Exited | −447,884 | −$16.1M | — |
| Guardant Health Inc | Exited | −302,307 | −$15.7M | — |
| Kymera Therapeutics Inc | New | +277,726 | +$15.7M | 2.4% |
| Boston Scientific Corp | Exited | −138,834 | −$14.9M | — |
Showing the 10 largest of 42 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Disc Medicine Inc | New | +299,464 | +$15.9M | 3.0% |
| Arcellx Inc | New | +215,223 | +$14.2M | 2.6% |
| Springworks Therapeutics Inc | Exited | −304,076 | −$13.4M | — |
| Glaukos Corp | Exited | −136,241 | −$13.4M | — |
| Exact Sciences Corp | Exited | −300,909 | −$13M | — |
| Verona Pharma PLC | Trimmed | −125,397 | −$11.9M | 5.5% |
| Vaxcyte Inc | Exited | −276,905 | −$10.5M | — |
| Adma Biologics Inc | Added | +525,416 | +$9.57M | 3.7% |
| NP Newamsterdam Pharma Company | New | +521,097 | +$9.44M | 1.8% |
| Merus N V | Trimmed | −170,996 | −$8.99M | 2.9% |
Showing the 10 largest of 42 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IT Intra-cellular Therapies Inc | Exited | −294,414 | −$24.6M | — |
| CP Crinetics Pharmaceuticals In | Exited | −453,376 | −$23.2M | — |
| Boston Scientific Corp | New | +178,156 | +$18M | 3.6% |
| Tg Therapeutics Inc | New | +400,644 | +$15.8M | 3.2% |
| Geron Corp | Exited | −3,893,327 | −$13.8M | — |
| Guardant Health Inc | New | +315,737 | +$13.5M | 2.7% |
| Springworks Therapeutics Inc | New | +304,076 | +$13.4M | 2.7% |
| Verona Pharma PLC | Trimmed | −206,516 | −$13.1M | 5.6% |
| Insulet Corp | New | +49,350 | +$13M | 2.6% |
| DO Day One Biopharmaceuticals I | Exited | −947,878 | −$12M | — |
Showing the 10 largest of 42 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Janux Therapeutics Inc | New | +383,602 | +$20.5M | 3.7% |
| Transmedics Group Inc | Exited | −114,247 | −$17.9M | — |
| Revolution Medicines Inc | New | +403,915 | +$17.7M | 3.2% |
| Exact Sciences Corp | New | +309,890 | +$17.4M | 3.1% |
| Vertex Pharmaceuticals Inc | Exited | −35,222 | −$16.4M | — |
| EL Establishment Labs Hldgs Inc | Exited | −357,003 | −$15.4M | — |
| Xenon Pharmaceuticals Inc | Added | +359,768 | +$14.1M | 4.8% |
| Repligen Corp | Exited | −88,714 | −$13.2M | — |
| Krystal Biotech Inc | Exited | −67,942 | −$12.4M | — |
| Healthequity Inc | New | +125,867 | +$12.1M | 2.2% |
Showing the 10 largest of 40 changes.
quarter ended September 30, 2024 · filed November 07, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Sarepta Therapeutics Inc | Exited | −181,669 | −$28.7M | — |
| Natera Inc | New | +155,650 | +$19.8M | 3.1% |
| Immunovant Inc | Exited | −695,428 | −$18.4M | — |
| Dexcom Inc | Exited | −160,096 | −$18.2M | — |
| Arcellx Inc | New | +214,298 | +$17.9M | 2.8% |
| Verona Pharma PLC | New | +572,928 | +$16.5M | 2.6% |
| Harrow Inc | New | +326,582 | +$14.7M | 2.3% |
| Bicara Therapeutics Inc | New | +562,391 | +$14.3M | 2.3% |
| AH Alphatec Hldgs Inc | Exited | −1,360,410 | −$14.2M | — |
| Geron Corp | New | +3,124,967 | +$14.2M | 2.2% |
Showing the 10 largest of 49 changes.
Loading...
